Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated:  11/15/2012
GSK Investigational Site
mi
from
Kennewick, WA
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias
Status: Enrolling
Updated: 11/15/2012
GSK Investigational Site
mi
from
Kennewick, WA
Click here to add this to my saved trials
Effects of Frequent Decision Making Among Patients With Serious Illnesses
Pilot Study of Repeated Decision Making in Patients
Status: Enrolling
Updated:  11/15/2012
Perelman Center for Advanced Medicine at the University of Pennsylvania
mi
from
Philadelphia, PA
Effects of Frequent Decision Making Among Patients With Serious Illnesses
Pilot Study of Repeated Decision Making in Patients
Status: Enrolling
Updated: 11/15/2012
Perelman Center for Advanced Medicine at the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effects of Repeated Decision Making Among Surrogates of Seriously Ill Patients
Pilot Study of Repeated Decision Making in Surrogates
Status: Enrolling
Updated:  11/15/2012
Perelman Center for Advanced Medicine at the University of Pennsylvania
mi
from
Philadelphia, PA
Effects of Repeated Decision Making Among Surrogates of Seriously Ill Patients
Pilot Study of Repeated Decision Making in Surrogates
Status: Enrolling
Updated: 11/15/2012
Perelman Center for Advanced Medicine at the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Early Detection of Breast Cancer Using Tomosynthesis Imaging
Early Detection of Breast Cancer Using Tomosynthesis Imaging
Status: Enrolling
Updated:  11/16/2012
DUMC Mammography, Duke South Hospital, 2nd floor
mi
from
Durham, NC
Early Detection of Breast Cancer Using Tomosynthesis Imaging
Early Detection of Breast Cancer Using Tomosynthesis Imaging
Status: Enrolling
Updated: 11/16/2012
DUMC Mammography, Duke South Hospital, 2nd floor
mi
from
Durham, NC
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of Alabama School of Medicine
mi
from
Birmingham, AL
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of Alabama School of Medicine
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of California Medical Center At Irvine-Orange
mi
from
Irvine, CA
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of California Medical Center At Irvine-Orange
mi
from
Irvine, CA
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Med College of Georgia
mi
from
Augusta, GA
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Med College of Georgia
mi
from
Augusta, GA
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of Chicago
mi
from
Chicago, IL
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of Kentucky
mi
from
Lexington, KY
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Franklin Square Hospital Center
mi
from
Baltimore, MD
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Franklin Square Hospital Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Cleveland Clinic
mi
from
Cleveland, OH
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
MetroHealth Med Ctr
mi
from
Cleveland, OH
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Hillcrest Hospital
mi
from
Cleveland, OH
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Hillcrest Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Case Western Reserve Univ
mi
from
Cleveland, OH
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Women and Infants Hospital of Rhode Island
mi
from
Providence, RI
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Women and Infants Hospital of Rhode Island
mi
from
Providence, RI
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
University of Virginia
mi
from
Charlottesville, VA
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated:  11/19/2012
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
A Phase I Study Of Intraperitoneal EGEN-001 (Il-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer
Status: Enrolling
Updated: 11/19/2012
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
The Effect of Meditation and Massage Therapy for Breast Cancer Patients Undergoing Tissue Reconstruction
The Effect of Meditation and Massage Therapy for Breast Cancer Patients Undergoing Autologous Tissue Reconstruction - A Pilot Study
Status: Enrolling
Updated:  11/26/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
The Effect of Meditation and Massage Therapy for Breast Cancer Patients Undergoing Tissue Reconstruction
The Effect of Meditation and Massage Therapy for Breast Cancer Patients Undergoing Autologous Tissue Reconstruction - A Pilot Study
Status: Enrolling
Updated: 11/26/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Stereotactic Radiosurgery in Treating Patients With Spinal Metastases
Cyberknife Radiosurgery for Improving Palliation of Metastatic Tumors of the Spine
Status: Enrolling
Updated:  11/27/2012
Boston University Cancer Research Center
mi
from
Boston, MA
Stereotactic Radiosurgery in Treating Patients With Spinal Metastases
Cyberknife Radiosurgery for Improving Palliation of Metastatic Tumors of the Spine
Status: Enrolling
Updated: 11/27/2012
Boston University Cancer Research Center
mi
from
Boston, MA
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
Scottsdale Medical Imaging, Ltd
mi
from
Scottsdale, AZ
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
Scottsdale Medical Imaging, Ltd
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
Silicon Valley Imaging
mi
from
Freemont, CA
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
Silicon Valley Imaging
mi
from
Freemont, CA
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
Cedar Sinai Medical Center
mi
from
Los Angeles, CA
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
Cedar Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
VA West Los Angles Medical Center
mi
from
Los Angeles, CA
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
VA West Los Angles Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
UCLA
mi
from
Los Angeles, CA
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
Stanford Univ Med Ctr
mi
from
Stanford, CA
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
SouthCoast Imaging Center
mi
from
Savannah, GA
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
SouthCoast Imaging Center
mi
from
Savannah, GA
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
University of Michigan Health System
mi
from
Ann Arbor, MI
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
Saint Lukes Hospital
mi
from
Kansas City, MO
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
Saint Lukes Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
John Cochran Veterans Administration
mi
from
Saint Louis, MO
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
John Cochran Veterans Administration
mi
from
Saint Louis, MO
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
Saint Louis University
mi
from
Saint Louis, MO
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
New York Presbyterian Weill Cornell
mi
from
New York, NY
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
New York Presbyterian Weill Cornell
mi
from
New York, NY
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated:  11/28/2012
University of Utah School of Medicine
mi
from
Salt Lake, UT
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques
Status: Enrolling
Updated: 11/28/2012
University of Utah School of Medicine
mi
from
Salt Lake, UT
Click here to add this to my saved trials
FDG Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer
[F-18]-Fluorodeoxyglucose (FDG) Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer
Status: Enrolling
Updated:  11/29/2012
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
FDG Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer
[F-18]-Fluorodeoxyglucose (FDG) Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer
Status: Enrolling
Updated: 11/29/2012
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Status: Enrolling
Updated:  11/29/2012
M.D. Anderson Cancer Center
mi
from
Houston, TX
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Status: Enrolling
Updated: 11/29/2012
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Dual-energy Contrast-enhanced (2D and 3D Mammography Versus Contrast-enhanced MRI)- A Pilot Study
Evaluation of Contrast-enhanced Mammography and Contrast-enhanced Breast Tomosynthesis: Comparison to Contrast-enhanced Breast MRI- A Pilot Study
Status: Enrolling
Updated:  11/30/2012
Rose Medical Center
mi
from
Denver, CO
Dual-energy Contrast-enhanced (2D and 3D Mammography Versus Contrast-enhanced MRI)- A Pilot Study
Evaluation of Contrast-enhanced Mammography and Contrast-enhanced Breast Tomosynthesis: Comparison to Contrast-enhanced Breast MRI- A Pilot Study
Status: Enrolling
Updated: 11/30/2012
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions
Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions
Status: Enrolling
Updated:  12/1/2012
University of Michigan
mi
from
Ann Arbor, MI
Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions
Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions
Status: Enrolling
Updated: 12/1/2012
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions
Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions
Status: Enrolling
Updated:  12/1/2012
University of Michigan
mi
from
Ann Arbor, MI
Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions
Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions
Status: Enrolling
Updated: 12/1/2012
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
Status: Enrolling
Updated:  12/4/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
Status: Enrolling
Updated: 12/4/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
Status: Enrolling
Updated:  12/4/2012
University of Wake Forest Baptist Medical Center
mi
from
Winston Salem, NC
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
Status: Enrolling
Updated: 12/4/2012
University of Wake Forest Baptist Medical Center
mi
from
Winston Salem, NC
Click here to add this to my saved trials
Outcome Measures in Infant/Early Childhood Lung Disease w/ Chest CT Scanning & Lung Function Testing
Differentiating Outcome Measures in Infant and Early Childhood Lung Disease Utilizing Controlled Ventilation Infant/Young Child Chest CT Scanning and Lung Function Testing
Status: Enrolling
Updated:  12/4/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Outcome Measures in Infant/Early Childhood Lung Disease w/ Chest CT Scanning & Lung Function Testing
Differentiating Outcome Measures in Infant and Early Childhood Lung Disease Utilizing Controlled Ventilation Infant/Young Child Chest CT Scanning and Lung Function Testing
Status: Enrolling
Updated: 12/4/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials